Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?

J Endocr Soc · 2026 · PMC13389710 · PMID 42487666

Europe PMC DOI

hedged sentence

0.0170

closest p · 0.3× alpha

0.0170

boldest claim

The sentences

nominally significantP = .017actually significant

A 2026 study by Candido et al in Italian patients with T2D receiving GLP-1RA therapy reported GLP1R rs6923761 frequencies consistent with broader Southern European estimates (MAF 18.3%) and identified a nominally significant association between Ser168 carrier status and greater 12-month weight loss (−3.2 kg, 95% CI −5.8 to −0.6 kg, P = .017) [ 62 ].

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.